Healthium launches TheruptorTM Novo, a patented dressing product for the management of chronic wounds like diabetic foot ulcers

Healthium launches TheruptorTM Novo, a patented dressing product for the management of chronic wounds like diabetic foot ulcers

National, 10th October 2022: Healthium Medtech, a global medical devices company focused on surgical, post-surgical and chronic care, today announced that the company has launched a new wound dressing portfolio TheruptorTM Novo for the management of chronic wounds like diabetic foot ulcers and leg ulcers. With the launch of TheruptorTM Novo, Healthium strengthens its existing portfolio of patented products in the advanced wound dressing segment.

India has almost 77 million patients affected with diabetes based on an NCBI survey. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364422/). Beyond well know complications like diabetic neuropathy and diabetic nephropathy the other major and rising complication is Diabetic Foot Ulcers. The lifetime risk of a person with diabetes having a foot ulcer has been reported to be as high as 25%. India witness almost 1 lakh registered amputations today due to complications of unmanaged diabetic foot ulcers. The treatment of foot ulcers is painful and costly. TheruptorTM Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing.

TheruptorTM Novo is an anti-microbial and non-toxic wound dressing with technology patented in US, India, EU and Canada. This product works on a physical kill mechanism of attract, bind and rupture formula – a patented technology that minimizes the development of resistant microbes and aids in the healing process. The entire dressing has positively charged cationic sites, which attracts the negatively charged microbes and ruptures their cell walls effectively, thus achieving anti-microbial protection. The anti-microbial technology is non-interfering and it doesn’t enter into the wound bed, making it persistent and effective for up to 7 days.

Speaking on the launch, Anish Bafna, CEO and MD, Healthium Medtech, said, “It gives us immense pleasure to launch TheruptorTM Novo using our indigenous patented technology. This is another great addition to our robust and dynamic product portfolio in the wound care and infection prevention segment. We will continue to add value to our customers by manufacturing high quality precision based devices and products that addresses the unmet gaps and bring patient safety to the fore. We will strive towards strengthening our presence, expand our product portfolio and deliver better patient care worldwide.”

Dr. Ashok Moharana, Chief Medical Officer, Healthium Medtech further adds, “The launch of Theruptor Novo reinforces our commitment towards precision products for clinicians and the patient community. At Healthium we are immensely focused on innovation, safety, quality and research for holistic solutions towards the clinical and the patient community. Theruptor Novo is a patented product for the management of chronic wounds which acts through a unique physical mechanism of action, as against most of the available dressings which acts through the pharmacological mechanism. The unique 3-D Hydrocellular substrate enables wicking action facilitating adequate exudate and moisture management and provides an optimal wound healing environment.”

Leave a Reply